Tesamorelin + Ipamorelin Blend
ALSO SOLD AS Tesa/Ipa
See the stack breakdown →Last reviewed 2026-10-30
Our read Opinion
No combination trials were found. Tesamorelin has approved-use human trial evidence, but blend efficacy and safety remain unestablished; ipamorelin is unapproved.
- Type
- Research-only / unapproved
- Regulatory status
- No FDA approval for the blend
- Compounding status
- Not allowed (blends excluded)
- FDA-approved indications
- None
- Evidence level
- Small/early human studies
- Routes studied
- —
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to reduce visceral fat and raise growth hormone
Tesamorelin activates the GHRH receptor and ipamorelin the ghrelin receptor, stimulating GH release. Increased GH/IGF-1 is not evidence of added benefit from combining them.
Not a peptide: a pre-mixed blend of Tesamorelin + Ipamorelin. Tesamorelin alone is FDA-approved as Egrifta for excess abdominal fat in HIV-infected adults with lipodystrophy, not weight-loss management. That approval does not cover ipamorelin or this blend.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
An approved ingredient does not make an approved combination. Tesamorelin’s indication-specific benefits should not be extrapolated to this blend or general fat-loss claims.
No news yet for this peptide.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.